Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastrointestinal adenocarcinoma; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, and BioInvent. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Часто задаваемые вопросы
В каком секторе работает Transgene SA (TNG)?
Transgene SA относится к сектору Здравоохранение.
Какова текущая цена акций Transgene SA (TNG)?
По последним данным, цена акций Transgene SA составляет 0,68 €, предыдущее закрытие — 0,68 €.
Выплачивает ли Transgene SA (TNG) дивиденды?
Нет, Transgene SA не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Transgene SA (TNG)?
У компании Transgene SA бета 0.732, что указывает на более низкую волатильность по сравнению с рынком в целом.
